Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correction 08 April 2022

Evolution of innovative drug R&D in China

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 21, 553-554 (2022)



The authors gratefully acknowledge Yunhe Qin (Pharmcube) and Yale Jiang (Tsinghua University) for their contribution to the work.

Updates & Corrections

  • Correction 08 April 2022: The article has been corrected to state that 35 new domestic drugs and vaccines were approved by the NMPA in 2021, rather than 69 as originally stated; 69 is actually the number of domestic and imported drugs approved in 2021.

Supplementary Information

  1. Supplementary information

Competing Interests

H.H., S.Y. and L.Z. are employees at Pharmcube. The other authors declare no competing interests.

Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links